ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.（SPRY）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · SPRY · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
8
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
ARS Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
SPRY 季度内部人买卖趋势
SPRY 内幕交易卖出 · SPRY 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · SPRY CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
SPRY 高管卖出股份 · SPRY 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Nov 13, 2025 | Dorsey Brian COO | Option | 21,828 | $14K | Form 4 |
| Nov 13, 2025 | Dorsey Brian COO | Sale | 21,828 | $190K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Option | 30,000 | $25K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 30,000 | $267K | Form 4 |
| Nov 12, 2025 | Chakma Justin Chief Business Officer | Sale | 136,380 | $1.21M⚡ | Form 4 |
| Nov 12, 2025 | Shah Pratik Director | Gift | 250,000 | — | Form 4 |
| Nov 12, 2025 | Shah Pratik Director | Gift | 100,000 | — | Form 4 |
| Aug 21, 2025 | Lowenthal Richard E PRESIDENT AND CEO · Director | Sale | 50,000 | $724K | Form 4 |
| Aug 21, 2025 | Scott Kathleen D. CFO | Option | 12,500 | $19K | Form 4 |
| Aug 21, 2025 | Scott Kathleen D. CFO | Sale | 12,500 | $188K | Form 4 |
| Aug 19, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale | 12,344 | $173K | Form 4 |
| Aug 20, 2025 | Tanimoto Sarina CHIEF MEDICAL OFFICER | Sale | 37,656 | $531K | Form 4 |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Option | 15,000 | $23K | Form 4 |
| Jul 1, 2025 | Karas Eric Chief Commercial Officer | Sale | 15,000 | $255K | Form 4 |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Option | 15,000 | $23K | Form 4 |
| Jun 18, 2025 | Karas Eric Chief Commercial Officer | Sale | 15,000 | $240K | Form 4 |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Option | 100,000 | $558K | Form 4 |
| May 20, 2025 | Fitzpatrick Alexander A Chief Legal Officer | Sale | 102,969 | $1.45M⚡ | Form 4 |
| May 20, 2025 | SAUNDERS BRENT L Director | Option | 120,000 | $121K | Form 4 |
| May 20, 2025 | SAUNDERS BRENT L Director | Sale | 120,000 | $1.71M⚡ | Form 4 |
| May 20, 2025 | Scott Kathleen D. CFO | Option | 50,000 | $75K | Form 4 |
| May 20, 2025 | Scott Kathleen D. CFO | Sale | 50,000 | $705K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Option | 27,493 | $133K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Option | 22,509 | $109K | Form 4 |
| Apr 7, 2025 | Shawver Laura Director | Sale | 50,002 | $615K | Form 4 |
Lowenthal Richard E
PRESIDENT AND CEO · Director
日期
Aug 21
股数
50,000
均价
$14.49
总金额
$724K
Fitzpatrick Alexander A
Chief Legal Officer
日期
May 20
股数
100,000
均价
$5.58
总金额
$558K
Fitzpatrick Alexander A
Chief Legal Officer
日期
May 20
股数
102,969
均价
$14.10
总金额
$1.45M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 SPRY 内幕交易
SPRY 内幕交易
ARS Pharmaceuticals, Inc.（SPRY）内幕交易数据来源于公司内部人（包括Karas Eric (Chief Commercial Officer), Chakma Justin (Chief Business Officer), Dorsey Brian (COO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。SPRY内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看ARS Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
SPRY 内幕交易 · 5个问题ARS Pharmaceuticals, Inc.（SPRY）的内部人包括高管和董事，如Karas Eric (Chief Commercial Officer), Chakma Justin (Chief Business Officer), Dorsey Brian (COO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026